We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+22.65%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.26B
AUM Growth
+$117M
Cap. Flow
-$20.7M
Cap. Flow %
-1.63%
Top 10 Hldgs %
85.03%
Holding
34
New
1
Increased
1
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
EHTH icon
eHealth
EHTH
+$2.26M
2
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$1.78M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$9.96M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.58M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$3.43M
4
PRTA icon
Prothena Corp
PRTA
+$1M
5
ABMD
Abiomed Inc
ABMD
+$984K

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.5B
$168M 13.25%
1,976,265
-85,108
-4% -$7.58M
UTHR icon
2
United Therapeutics
UTHR
$22.1B
$133M 10.49%
633,534
-1,272
-0.2% -$284K
INSM icon
3
Insmed
INSM
$29B
$126M 9.95%
5,840,398
– –
ABMD
4
DELISTED
Abiomed Inc
ABMD
$121M 9.53%
490,754
-3,643
-0.7% -$984K
RVNC
5
DELISTED
Revance Therapeutics, Inc.
RVNC
$119M 9.4%
4,405,039
– –
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$103M 8.13%
9,847,774
– –
PRTA icon
7
Prothena Corp
PRTA
$473M
$100M 7.91%
1,649,777
-31,700
-2% -$1M
BIIB icon
8
Biogen
BIIB
$30.1B
$96.4M 7.62%
360,981
– –
STAA icon
9
STAAR Surgical
STAA
$1.24B
$77.4M 6.12%
1,096,882
-9,685
-0.9% -$829K
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$33.3M 2.64%
851,409
– –
KPTI icon
11
Karyopharm Therapeutics
KPTI
$47.6M
$30.7M 2.43%
374,769
– –
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$5.07B
$27.5M 2.17%
1,678,196
– –
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$298M
$21.4M 1.69%
2,166,156
-325,044
-13% -$3.43M
GOSS icon
14
Gossamer Bio
GOSS
$88.9M
$21M 1.66%
1,750,651
– –
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.81B
$14.7M 1.16%
612,600
– –
ALKS icon
16
Alkermes
ALKS
$8.26B
$13.5M 1.07%
603,400
– –
ANAB icon
17
AnaptysBio
ANAB
$1.71B
$11M 0.87%
431,024
– –
ALGN icon
18
Align Technology
ALGN
$12.3B
$9.18M 0.73%
44,305
– –
EHTH icon
19
eHealth
EHTH
$39.1M
$7.73M 0.61%
1,977,993
+323,300
+20% +$2.26M
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$5.99M 0.47%
2,330,504
– –
KZR
21
DELISTED
Kezar Life Sciences
KZR
$5.65M 0.45%
65,620
– –
CYTK icon
22
Cytokinetics
CYTK
$10.6B
$5.41M 0.43%
111,717
– –
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$5.32M 0.42%
4,473,967
– –
TVTX icon
24
Travere Therapeutics
TVTX
$5.68B
$4.09M 0.32%
166,069
– –
PRVB
25
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1.76M 0.14%
+390,800
New +$1.78M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q3 2022 Portfolio in Review

As of Q3 2022, Palo Alto Investors held 34 positions worth $1.26B, up 10% from $1.15B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Palo Alto Investors's Q3 2022 filing shows 1 new, 1 increased, 6 reduced and 2 closed positions. Its largest new stake was Provention Bio, Inc. Common Stock: 390,800 shares worth $1.76M. The largest sale was Epizyme, Inc, an estimated $9.96M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q3 2022 buy was Provention Bio, Inc. Common Stock: 390,800 shares worth $1.76M.
  • Palo Alto Investors added most to eHealth in Q3 2022, an estimated $2.26M increase.
  • Palo Alto Investors's biggest Q3 2022 reduction was BioMarin Pharmaceuticals, cutting an estimated $7.58M.
  • Palo Alto Investors fully exited Epizyme, Inc in Q3 2022, selling an estimated $9.96M.
  • Palo Alto Investors's ten largest holdings make up 85% of its $1.26B portfolio in Q3 2022.
  • Palo Alto Investors opened 1 new position and closed 2 in Q3 2022.
  • Palo Alto Investors's portfolio value rose 10% quarter-over-quarter to $1.26B.

Based on Palo Alto Investors's 13F filing for Q3 2022, filed 14 Nov 2022.